A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours
Publication status
publishedExternal links
Journal / series
Nature CommunicationsVolume
Pages / Article No.
Publisher
Nature Publishing GroupMore
Show all metadata